Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

about

Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.Welcome to the Journal of Surgery and Science!

P2860

Q35402408-23EBFC10-46F3-42D7-91D0-8D1CACA2E5D2 Q42429773-3BF1184E-15EF-4367-BFE4-82CB1CB76E23 Q42991659-3599A174-12B2-4150-AE9A-F3E2DBA84563

P2860

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

Item

http://www.wikidata.org/entity/Q33576608

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@ast

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@en

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

@nl

type

Item

label

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@ast

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@en

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

@nl

prefLabel

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@ast

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@en

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

@nl

P1476

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

@en

P2093

Charles E Chalfant

http://www.w3.org/2001/XMLSchema#string

L Alexis Hoeferlin

http://www.w3.org/2001/XMLSchema#string

Margaret A Park

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted therapy for breast cancer

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Cancer statistics, 2013

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

ERBB receptors and cancer: the complexity of targeted inhibitors

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

P304

3-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24818173

http://www.w3.org/2001/XMLSchema#string

P921

overexpression

P932

4012677

http://www.w3.org/2001/XMLSchema#string

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

about

P2860

P2860

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932